Khing Djien Oei sold $662k of CYPH
director at LEAP THERAPEUTICS, INC.. 168,750 shares at an average of $3.92, traded Sep 25, 2026, filed Sep 25, 2026.
Score components
- +15RoleDirector
- +20Trade size$662k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-111063, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | SOpen-market sale Common Stock | -168,750 | $3.92 | $662k | 0 | 19 d ago |
Related signals
Other insiders at LEAP THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | LEAP THERAPEUTICS, INC. | Patricia A. Martin director | $193k 50,000 shares | -30% | |
| 26Weak | CYPHsell LEAP THERAPEUTICS, INC. | Thomas John Dietz director | $34k 20,000 shares | -13% | |
| 31Weak | CYPHsell LEAP THERAPEUTICS, INC. | Christopher Mirabelli Chairman of the Board | $43k 60,000 shares | -32% | |
| 73Notable | LEAP THERAPEUTICS, INC. | James H Cavanaugh director | $822k 261,840 shares | -100% | |
| 85Strong | LEAP THERAPEUTICS, INC. | Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. | $2.1M 676,319 shares | -100% | |
| 75Notable | LEAP THERAPEUTICS, INC. | Christopher Mirabelli Chairman of the Board | $2.1M 676,319 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.